{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(4)"],"submitter":["Schmitz-Winnenthal FH"],"funding":["VAXIMM AG"],"pubmed_abstract":["VXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated <i>Salmonella</i> typhi carrying an expression plasmid encoding VEGFR2, an antigen expressed on tumor vasculature and a stable and accessible target for anti-angiogenic intervention. A recent randomized, placebo-controlled, phase I dose-escalation trial in advanced pancreatic cancer patients demonstrated safety, immunogenicity and transient, T-cell response-related anti-angiogenic activity of four priming vaccinations applied within one week. We here evaluated whether monthly boost vaccinations are safe and can sustain increased frequencies of vaccine-specific T cells. Patients with advanced pancreatic cancer were randomly assigned at a ratio of 2:1 to priming with VXM01 followed by up to six monthly boost vacci"],"journal":["Oncoimmunology"],"pagination":["e1303584"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5889207"],"repository":["biostudies-literature"],"pubmed_title":["A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer."],"pmcid":["PMC5889207"],"pubmed_authors":["Springer M","Wieckowski S","Knebel P","Koc R","Haefeli WE","Springfeld C","Buchler MW","Lubenau H","Podola L","Mikus G","Grenacher L","Schmitz-Winnenthal FH","Bucur M","Hohmann N","Beckhove P","Schmidt T","Breiner KM","Keller AV","Friedrich T"],"additional_accession":[]},"is_claimable":false,"name":"A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.","description":"VXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated <i>Salmonella</i> typhi carrying an expression plasmid encoding VEGFR2, an antigen expressed on tumor vasculature and a stable and accessible target for anti-angiogenic intervention. A recent randomized, placebo-controlled, phase I dose-escalation trial in advanced pancreatic cancer patients demonstrated safety, immunogenicity and transient, T-cell response-related anti-angiogenic activity of four priming vaccinations applied within one week. We here evaluated whether monthly boost vaccinations are safe and can sustain increased frequencies of vaccine-specific T cells. Patients with advanced pancreatic cancer were randomly assigned at a ratio of 2:1 to priming with VXM01 followed by up to six monthly boost vacci","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018","modification":"2026-04-07T23:22:49.723Z","creation":"2019-03-26T22:37:18Z"},"accession":"S-EPMC5889207","cross_references":{"pubmed":["29632710"],"doi":["10.1080/2162402X.2017.1303584","10.1080/2162402x.2017.1303584"]}}